Mark J Siedner1, Courtney K Ng2, Ingrid V Bassett3, Ingrid T Katz4, David R Bangsberg5, Alexander C Tsai6. 1. Center for Global Health Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital Harvard Medical School. 2. Center for Global Health. 3. Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital Harvard Medical School Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital. 4. Center for Global Health Harvard Medical School Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 5. Center for Global Health Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital Harvard Medical School Mbarara University of Science and Technology, Uganda. 6. Center for Global Health Harvard Medical School Mbarara University of Science and Technology, Uganda Department of Psychiatry, Massachusetts General Hospital, Boston.
Abstract
BACKGROUND: Both population- and individual-level benefits of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) are contingent on early diagnosis and initiation of therapy. We estimated trends in disease status at presentation to care and at ART initiation in sub-Saharan Africa. METHODS: We searched PubMed for studies published January 2002-December 2013 that reported CD4 cell count at presentation or ART initiation among adults in sub-Saharan Africa. We abstracted study sample size, year(s), and mean CD4 count. A random-effects meta-regression model was used to obtain pooled estimates during each year of the observation period. RESULTS: We identified 56 articles reporting CD4 count at presentation (N = 295 455) and 71 articles reporting CD4 count at ART initiation (N = 549 702). The mean estimated CD4 count in 2002 was 251 cells/µL at presentation and 152 cells/µL at ART initiation. During 2002-2013, neither CD4 count at presentation (β = 5.8 cells/year; 95% confidence interval [CI], -10.7 to 22.4 cells/year), nor CD4 count at ART initiation (β = -1.1 cells/year; 95% CI, -8.4 to 6.2 cells/year) increased significantly. Excluding studies of opportunistic infections or prevention of mother-to-child transmission did not alter our findings. Among studies conducted in South Africa (N = 14), CD4 count at presentation increased by 39.9 cells/year (95% CI, 9.2-70.2 cells/year; P = .02), but CD4 count at ART initiation did not change. CONCLUSIONS: CD4 counts at presentation to care and at ART initiation in sub-Saharan Africa have not increased over the past decade. Barriers to presentation, diagnosis, and linkage to HIV care remain major challenges that require attention to optimize population-level benefits of ART.
BACKGROUND: Both population- and individual-level benefits of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) are contingent on early diagnosis and initiation of therapy. We estimated trends in disease status at presentation to care and at ART initiation in sub-Saharan Africa. METHODS: We searched PubMed for studies published January 2002-December 2013 that reported CD4 cell count at presentation or ART initiation among adults in sub-Saharan Africa. We abstracted study sample size, year(s), and mean CD4 count. A random-effects meta-regression model was used to obtain pooled estimates during each year of the observation period. RESULTS: We identified 56 articles reporting CD4 count at presentation (N = 295 455) and 71 articles reporting CD4 count at ART initiation (N = 549 702). The mean estimated CD4 count in 2002 was 251 cells/µL at presentation and 152 cells/µL at ART initiation. During 2002-2013, neither CD4 count at presentation (β = 5.8 cells/year; 95% confidence interval [CI], -10.7 to 22.4 cells/year), nor CD4 count at ART initiation (β = -1.1 cells/year; 95% CI, -8.4 to 6.2 cells/year) increased significantly. Excluding studies of opportunistic infections or prevention of mother-to-child transmission did not alter our findings. Among studies conducted in South Africa (N = 14), CD4 count at presentation increased by 39.9 cells/year (95% CI, 9.2-70.2 cells/year; P = .02), but CD4 count at ART initiation did not change. CONCLUSIONS: CD4 counts at presentation to care and at ART initiation in sub-Saharan Africa have not increased over the past decade. Barriers to presentation, diagnosis, and linkage to HIV care remain major challenges that require attention to optimize population-level benefits of ART.
Authors: Dorita Avila; Keri N Althoff; Catrina Mugglin; Kara Wools-Kaloustian; Manuel Koller; François Dabis; Denis Nash; Thomas Gsponer; Somnuek Sungkanuparph; Catherine McGowan; Margaret May; David Cooper; Cleophas Chimbetete; Marcelo Wolff; Ann Collier; Hamish McManus; Mary-Ann Davies; Dominique Costagliola; Brenda Crabtree-Ramirez; Romanee Chaiwarith; Angela Cescon; Morna Cornell; Lameck Diero; Praphan Phanuphak; Adrien Sawadogo; Jochen Ehmer; Serge P Eholie; Patrick C K Li; Matthew P Fox; Neel R Gandhi; Elsa González; Christopher K C Lee; Christopher J Hoffmann; Andrew Kambugu; Olivia Keiser; Rossana Ditangco; Hans Prozesky; Fiona Lampe; Nagalingeswaran Kumarasamy; Mari Kitahata; Emmanuel Lugina; Rita Lyamuya; Saphonn Vonthanak; Valeria Fink; Antonella d'Arminio Monforte; Paula Mendes Luz; Yi-Ming A Chen; Albert Minga; Jordi Casabona; Albert Mwango; Jun Y Choi; Marie-Louise Newell; Elizabeth A Bukusi; Kapella Ngonyani; Tuti P Merati; Juliana Otieno; Mwebesa B Bosco; Sam Phiri; Oon T Ng; Kathryn Anastos; Jürgen Rockstroh; Ignacio Santos; Shinichi Oka; Geoffrey Somi; Christoph Stephan; Ramon Teira; Deo Wabwire; Gilles Wandeler; Andrew Boulle; Peter Reiss; Robin Wood; Benjamin H Chi; Carolyn Williams; Jonathan A Sterne; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: Mark J Siedner; Nicholas Musinguzi; Alexander C Tsai; Conrad Muzoora; Annet Kembabazi; Sheri D Weiser; John Bennett; Peter W Hunt; Jeffrey N Martin; Jessica E Haberer; David R Bangsberg Journal: AIDS Date: 2014-01-14 Impact factor: 4.177
Authors: Catherine R Lesko; Stephen R Cole; Anne Zinski; Charles Poole; Michael J Mugavero Journal: Clin Infect Dis Date: 2013-08-06 Impact factor: 9.079
Authors: Jacob O Odhiambo; Timothy A Kellogg; Andrea A Kim; Lucy Ng'ang'a; Irene Mukui; Mamo Umuro; Ibrahim Mohammed; Kevin M De Cock; Davies O Kimanga; Sandra Schwarcz Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai Journal: J Int AIDS Soc Date: 2013-11-13 Impact factor: 5.396
Authors: Jan A C Hontelez; Mark N Lurie; Till Bärnighausen; Roel Bakker; Rob Baltussen; Frank Tanser; Timothy B Hallett; Marie-Louise Newell; Sake J de Vlas Journal: PLoS Med Date: 2013-10-22 Impact factor: 11.069
Authors: Mark J Siedner; Ingrid V Bassett; Ingrid T Katz; Courtney K Ng; David R Bangsberg; Alexander C Tsai Journal: Clin Infect Dis Date: 2015-12-13 Impact factor: 9.079
Authors: Sae Takada; Viola Nyakato; Akihiro Nishi; A James O'Malley; Bernard Kakuhikire; Jessica M Perkins; David R Bangsberg; Nicholas A Christakis; Alexander C Tsai Journal: Soc Sci Med Date: 2019-05-20 Impact factor: 4.634
Authors: Mark W Tenforde; Margaret Mokomane; Tshepo Leeme; Raju K K Patel; Nametso Lekwape; Chandapiwa Ramodimoosi; Bonno Dube; Elizabeth A Williams; Kelebeletse O Mokobela; Ephraim Tawanana; Tlhagiso Pilatwe; William J Hurt; Hannah Mitchell; Doreen L Banda; Hunter Stone; Mooketsi Molefi; Kabelo Mokgacha; Heston Phillips; Paul C Mullan; Andrew P Steenhoff; Yohana Mashalla; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2016-05-31 Impact factor: 25.391
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272